VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
VCEL
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
VCELVericel Corporation
$58.65$3.0B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
VCEL logo

Vericel Corporation

VCEL
NASDAQ · Cell & Gene Therapy
$58.65
At close - Nov 18, 4:00 PM EST - USD
Market Cap$3B
P/E93.3x
52W High$59.75
Volume832.42K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q2

Accelerating Revenue Growth Masks SBC Dilution Risk

Vericel's revenue momentum is accelerating, with 22.5% YoY growth in 2026Q2 and gross margin expansion to 72.8%, driven by strong demand for its cell therapy products.

GrowthAccelerating
ProfitabilityStable
ValuationExpensive
TechnicalsStrong
Explore valuation models
MARKET ACTION

VCEL price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

9/12 Beats

EPS beat 9 of last 12 quarters

02

Valuation risk

+277% Peers

P/E is 277% above peer median

03

Market leadership

RS 94 · Leader

High momentum (Outperforming 94% of market)

04

Strong Uptrend

Strong Trend

Price > 20DMA > 50DMA > 200DMA

Next CatalystEstimated earnings · Feb 5

Market performance

Price History →

Trailing total returns as of 11/19/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
VCEL+64.70%
S&P 500 (^GSPC)+6.88%
1-Year Return
VCEL+50.27%
S&P 500 (^GSPC)+10.62%
3-Year Return
VCEL+59.94%
S&P 500 (^GSPC)+62.47%
5-Year Return
VCEL+37.48%
S&P 500 (^GSPC)+56.28%
02

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis
Trailing P/E5Y Low
93.3x
Forward P/E
109.6x
EV/EBITDA0th %ile
73.5x
FCF YieldCash Flow
1.5%

Valuation vs 5-Year History

Multiple Range
Metric
Current
5Y Median
Historical Range
Percentile
P/E
93.3x
274.5x
0th· Low
EV/EBITDA
73.5x
285.5x
0th· Low
Price/FCF
65.3x
123.0x
0th· Low
Current Multiple
5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection
Bear$1.19-98.0%
Base (Fair)$46.50-18.4%
Bull$6.38-89.1%
$1.19 Bear$46.50 Base$6.38 Bull
Current Market Price: $58.65
Trades at a 26.1% premium to Base DCF ($46.50)
Open DCF & Valuation Models →Chart Terminal ↗

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$276M+16.5% YoY
Net income FY25
$17M+59.4% YoY
Free cash flow FY25
$25M+525.9% YoY
Operating margin FY25
4%+2.1 pts YoY
ROIC (FY25)2.5%
Avg ROIC 5Y-2%
ROE (TTM)9.1%
Piotroski Score8 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate9/12 (75%)
Revenue Beat Rate7/12 (58%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 5, 2026
$0.27+371.6%
vs $0.06
$85M+9.5%
vs $78M
Q3 2026
Jul 30, 2026
$0.04+238.2%
vs -$0.03
$77M+6.5%
vs $73M
Q2 2026
May 7, 2026
-$0.12+20.0%
vs -$0.15
$68M+7.5%
vs $64M
Q1 2026
Feb 26, 2026
$0.45+0.0%
vs $0.45
$93M+2.1%
vs $91M
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
Defense World·3d ago
Aberdeen Group plc Buys 1,454,012 Shares of Vericel Corporation $VCEL

Aberdeen Group plc raised its stake in Vericel Corporation (NASDAQ: VCEL) by 204.7% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,164,250 shares of the biotechnology company's stock after purchasing an additional 1,454,012 shares during the period. Aberdeen

GlobeNewsWire·5d ago
Vericel to Present at the Stephens Annual Investment Conference on Wednesday, November 18, 2026

BURLINGTON, Mass., Nov. 13, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the Stephens Annual Investment Conference at 4:30 p.m. ET (3:30 p.m. CT) on Wednesday, November 18, 2026.

Zacks Investment Research·Nov 10, 2026
Earnings Estimates Moving Higher for Vericel (VCEL): Time to Buy?

Vericel Corporation (VCEL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

MarketBeat·Nov 6, 2026
Vericel Q3 Earnings Call Highlights

Vericel NASDAQ: VCEL raised its full-year revenue and profitability outlook after third-quarter sales rose 26%, led by growth in its MACI cartilage repair product and a record quarter for its burn care business.

Filtered for Vericel CorporationMore Headlines
04

Compare before deciding

Benchmark VCEL against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Vericel Corporation (VCEL)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
VCEL logoVCELVericel CorporationCurrent
$58.65$3B93.2616.45%10.27%9.09%—
MGTX logoMGTXMeiraGTx Holdings plc
$8.32$770.51M10.30144.57%19.48%85.3%—
RCKT logoRCKTRocket Pharmaceuticals, Inc.
$2.11$230.4M-14.85——-5.34%—
FATE logoFATEFate Therapeutics, Inc.
$1.05$122.39M-1.04-51.24%-2619.64%-73.92%—
AGIO logoAGIOAgios Pharmaceuticals, Inc.
$29.68$1.77B-4.7548.03%-264.76%-34.63%—
NTLA logoNTLAIntellia Therapeutics, Inc.
$9.77$1.1B-3.2116.92%-805.75%-64.73%—

Compare VCEL vs Peers

Vericel Corporation (VCEL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs MGTX

Most directly comparable listed peer for VCEL.

Scale Benchmark

vs SYK

Larger-name benchmark to compare VCEL against a more recognizable public peer.

Peer Set

Compare Top 5

vs MGTX, RCKT, FATE, AGIO

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

VCEL SEC Filings & Documents

Vericel Corporation (VCEL) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Jul 30, 2026·SEC

Material company update

May 18, 2026·SEC

Material company update

May 7, 2026·SEC

10-K Annual Reports

3
FY 2026

Feb 26, 2026·SEC

FY 2025

Feb 27, 2025·SEC

FY 2024

Feb 29, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

Jul 30, 2026·SEC

FY 2026

May 7, 2026·SEC

FY 2025

Nov 6, 2025·SEC

Get notified when VCEL posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

VCEL Frequently Asked Questions

Vericel Corporation (VCEL) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Vericel Corporation's revenue?

Vericel Corporation (VCEL) reported $324.2M in revenue over the trailing twelve months. Revenue was $276.3M in fiscal year 2025. That is 17166% more than the $1.6M of fiscal year 1996.

How fast is Vericel Corporation growing?

Vericel Corporation (VCEL) grew revenue by 25.3% over the trailing twelve months, compared with the twelve months before.

Is VCEL profitable?

Yes. Vericel Corporation (VCEL) earned $33.3M in net income over the trailing twelve months (a 10.3% net margin).

Dividend & Returns
What is VCEL's return on equity?

Vericel Corporation (VCEL) had a return on equity (ROE) of 9.1% over the trailing twelve months. That is below the market's typical 10-15%.

What is Vericel Corporation's free cash flow?

Vericel Corporation (VCEL) generated $45.9M in free cash flow over the trailing twelve months.

What if you invested $1,000 in VCEL back in 1996?

Total return calculator · dividends reinvested · 30+ years of data

See returns →